9. CGMs move into hospitalsAs the COVID-19 pandemic ramped up in March, the FDA issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance, which included continuous glucose monitors made by companies such as Dexcom and Abbott, appears to have opened up an entirely new market for CGMs.
Dexcom CEO Kevin Sayer, in fact, recently told MDO that nearly 250 U.S. hospitals contacted the company amid the pandemic, with more than 100 using the G6 CGM to manage patients’ glucose values so staff can respond to other health issues. – CN